These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9112505)

  • 1. Predictors of success and risk factors for attrition in the use of intracavernous injection.
    Gupta R; Kirschen J; Barrow RC; Eid JF
    J Urol; 1997 May; 157(5):1681-6. PubMed ID: 9112505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What nonresponse to intracavernous injection really indicates: a determination by quantitative analysis.
    Elhanbly S; Schoor R; Elmogy M; Ross L; Hegazy A; Niederberger C
    J Urol; 2002 Jan; 167(1):192-6. PubMed ID: 11743303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term intracavernous therapy responders can potentially switch to sildenafil citrate after radical prostatectomy.
    Raina R; Lakin MM; Agarwal A; Ausmundson S; Montague DK; Zippe CD
    Urology; 2004 Mar; 63(3):532-7; discussion 538. PubMed ID: 15028452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nocturnal penile tumescence activity unchanged after long-term intracavernous injection therapy.
    Maniam P; Seftel AD; Corty EW; Rutchik SD; Hampel N; Althof SE
    J Urol; 2001 Mar; 165(3):830-2; discussion 832-3. PubMed ID: 11176480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate.
    Israilov S; Niv E; Livne PM; Shmueli J; Engelstein D; Segenreich E; Baniel J
    Int J Impot Res; 2002 Feb; 14(1):38-43. PubMed ID: 11896476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Logistic regression and survival analysis of 450 impotent patients treated with injection therapy: long-term dropout parameters.
    Vardi Y; Sprecher E; Gruenwald I
    J Urol; 2000 Feb; 163(2):467-70. PubMed ID: 10647656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of long-term outcomes of penile prostheses and intracavernosal injection therapy.
    Sexton WJ; Benedict JF; Jarow JP
    J Urol; 1998 Mar; 159(3):811-5. PubMed ID: 9474156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penile scarring with intracavernous injection therapy using prostaglandin E1: a risk factor analysis.
    Chen RN; Lakin MM; Montague DK; Ausmundson S
    J Urol; 1996 Jan; 155(1):138-40. PubMed ID: 7490812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follow up outcome of intracavernous papaverine.
    al-Juburi AZ; O'Donnell PD
    J Ark Med Soc; 1990 Mar; 86(10):383-5. PubMed ID: 2138146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses.
    Bechara A; Casabé A; Chéliz G; Romano S; Fredotovich N
    J Urol; 1996 Mar; 155(3):913-4. PubMed ID: 8583605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [3 years' experience with intracavernous auto-injection therapy].
    Weiske WH
    Urologe A; 1989 Sep; 28(5):253-6. PubMed ID: 2815435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intracavernous auto-injection therapy with papaverine phentolamine via an auto-injection pen for patients with an erectile dysfunction: similar results achieved in family practice and urology].
    de Boer BJ; Lycklama a Nijeholt AA; Kleinjans HA
    Ned Tijdschr Geneeskd; 2001 Apr; 145(16):783-7. PubMed ID: 11346917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy of a new formulation of prostaglandin E1 as treatment for erectile failure.
    Godschalk M; Gheorghiu D; Chen J; Katz PG; Mulligan T
    J Urol; 1996 Mar; 155(3):915-7. PubMed ID: 8583606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
    Segenreich E; Israilov S; Shmueli J; Simon D; Baniel J; Livne P
    Harefuah; 1998 May; 134(9):673-8, 750. PubMed ID: 10909609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of prostaglandin E1 and its main metabolites after intracavernous injection and short-term infusion of prostaglandin E1 in patients with erectile dysfunction.
    Cawello W; Schweer H; Dietrich B; Seyberth HW; Albrecht D; Fox A; Hohmuth H
    J Urol; 1997 Oct; 158(4):1403-7. PubMed ID: 9302131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
    Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
    Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracavernous injection therapy for male erectile dysfunction.
    Fallon B
    Urol Clin North Am; 1995 Nov; 22(4):833-45. PubMed ID: 7483132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prostaglandin E1 injection in erectile dysfunction. Current diagnostic and therapeutic possibilities].
    Schrey A
    Fortschr Med; 1990 Oct; 108(30):577-80. PubMed ID: 2245960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The causes of patient dropout from penile self-injection therapy for impotence.
    Mulhall JP; Jahoda AE; Cairney M; Goldstein B; Leitzes R; Woods J; Payton T; Krane RJ; Goldstein I
    J Urol; 1999 Oct; 162(4):1291-4. PubMed ID: 10492182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does prostaglandin E1 therapy modify the intracavernous musculature?
    Wespes E; Sattar AA; Noël JC; Schulman CC
    J Urol; 2000 Feb; 163(2):464-6. PubMed ID: 10647655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.